1
|
DAVY J, WEISSENBURGER J, ERTZBISCHOFF O, POIRIER J, BIOUR M, GAYET J, CHEYMOU G, MOTTE G. Comparison of Electrophysiological Effects of Quinidine and Hydroquinidine in Anesthetized Dogs. J Cardiovasc Electrophysiol 2008. [DOI: 10.1111/j.1540-8167.1991.tb01707.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL, Goldstein SA. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97:10613-8. [PMID: 10984545 PMCID: PMC27073 DOI: 10.1073/pnas.180223197] [Citation(s) in RCA: 319] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Drug-induced long QT syndrome (LQTS) is a prevalent disorder of uncertain etiology that predisposes to sudden death. KCNE2 encodes MinK-related peptide 1 (MiRP1), a subunit of the cardiac potassium channel I(Kr) that has been associated previously with inherited LQTS. Here, we examine KCNE2 in 98 patients with drug-induced LQTS, identifying three individuals with sporadic mutations and a patient with sulfamethoxazole-associated LQTS who carried a single-nucleotide polymorphism (SNP) found in approximately 1.6% of the general population. While mutant channels showed diminished potassium flux at baseline and wild-type drug sensitivity, channels with the SNP were normal at baseline but inhibited by sulfamethoxazole at therapeutic levels that did not affect wild-type channels. We conclude that allelic variants of MiRP1 contribute to a significant fraction of cases of drug-induced LQTS through multiple mechanisms and that common sequence variations that increase the risk of life-threatening drug reactions can be clinically silent before drug exposure.
Collapse
Affiliation(s)
- F Sesti
- Departments of Pediatrics and Cellular and Molecular Physiology, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT 06536, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Latini R, Magnolfi G, Zordan R, Ferrari M, Padrini R, Piovan D, Pecorari T, Bottazzi L, Guiducci U. Antiarrhythmic drug plasma concentrations in ambulatory patients. Ann Pharmacother 1996; 30:298-300. [PMID: 8833571 DOI: 10.1177/106002809603000319] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
|
4
|
Abstract
The possible effect of amiodarone administration on the effectiveness and complications of electrical cardioversion of supraventricular tachyarrhythmias has not been properly assessed. To investigate the effects of amiodarone on cardioversion, we performed 130 electrical cardioversion procedures in 116 patients who were receiving long-term amiodarone therapy (group I) and 44 cardioversion procedures in 43 patients who were receiving intravenous infusions of amiodarone (group II). All patients in groups I and II had atrial fibrillation or flutter. In group I, there was a higher incidence of ventricular premature beats than in a control group of patients who underwent 100 cardioversions; one patient had severe bradycardia with asystole, which was resolved satisfactorily. In group II there was a higher incidence of sinus bradycardia and ventricular premature beats. It was concluded that electrical cardioversion of supraventricular arrhythmias can be safely performed in patients who are receiving long-term oral or intravenous amiodarone therapy if the usual precautions are observed.
Collapse
Affiliation(s)
- J Sagristà-Sauleda
- Servicio de Cardiologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain
| | | | | |
Collapse
|
5
|
Kudenchuk PJ, Kron J, Walance CG, Cutler JE, Griffith KK, McAnulty JH. Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease. Am J Cardiol 1990; 66:725-30. [PMID: 2399890 DOI: 10.1016/0002-9149(90)91138-v] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Forty-nine patients with coronary artery disease and documented clinical sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were studied twice in the drug-free state and twice during treatment with an identical antiarrhythmic medication at therapeutic plasma concentrations using an identical programmed electrical stimulation protocol. Tested drugs included procainamide, quinidine, disopyramide and phenytoin. During their 2 paired tests, 11 patients had nearly identical therapeutic plasma concentrations of antiarrhythmic agents (group I) and 38 patients had therapeutic plasma concentrations, but with more variation in drug levels between otherwise identical paired drug tests (group II). Overall, 71% of patients had inducible sustained VT or VF during drug testing. Induced ventricular arrhythmias were not reproducible in 45% of group I patients, despite restudy at nearly identical therapeutic plasma concentrations of an identical antiarrhythmic agent. Induced arrhythmias were also not reproducible in 16% of group II patients. This variability could not be attributed to the electrophysiologic characteristics of the patients studied. Drug trials directed by programmed stimulation should be cautiously interpreted because time-associated changes can mimic a change attributed to a beneficial or deleterious drug effect.
Collapse
Affiliation(s)
- P J Kudenchuk
- Department of Medicine, Oregon Health Sciences University, Portland
| | | | | | | | | | | |
Collapse
|
6
|
Latini R, Maggioni AP, Cavalli A. Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status. Clin Pharmacokinet 1990; 18:91-103. [PMID: 2180615 DOI: 10.2165/00003088-199018020-00001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- R Latini
- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | | | |
Collapse
|
7
|
McCollam PL, Bauman JL. New Concepts in Antiarrhythmic Drug Monitoring. J Pharm Pract 1989. [DOI: 10.1177/089719008900200608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Patrick L. McCollam
- University of Illinois at Chicago, Department of Pharmacy Practice, 833 S Wood St (M/C 886), Chicago, IL 60512
| | - Jerry L. Bauman
- University of Illinois at Chicago, Department of Pharmacy Practice, 833 S Wood St (M/C 886), Chicago, IL 60512
| |
Collapse
|
8
|
Abstract
Plasma concentration monitoring of antiarrhythmic agents is valuable, but it is often misused or overemphasized in therapeutic decision-making. There are strict requirements for its appropriate use that are often not met--for both the newer and even the conventional antiarrhythmic drugs. For maximum value, there must be a reliable, accurate relation between the plasma drug concentration and drug action, a relation closer than that between dosage and drug action. The time of sample collection is important--most guidelines are based on "trough" plasma concentrations measured after steady-state equilibrium has been achieved. The use of an accurate, sensitive and specific assay is crucial to the value of plasma concentration monitoring guidelines. However, for agents having active metabolites, monitoring the concentration of only the parent drug can be misleading and limits (but does not necessarily eliminate) the value of plasma concentration monitoring guidelines for these agents. Plasma concentration monitoring of most antiarrhythmic agents is of value for certain specific purposes: to determine compliance to antiarrhythmic therapy, to detect and analyze possible drug interactions, to assess the benefit to risk ratio for increasing the dose of a particular antiarrhythmic agent, to maintain a stable drug effect in the presence of a patient's changing clinical condition and, to a limited extent, to assess the role of an agent in causing an adverse drug reaction. The importance of understanding the assay methods currently in use, as well as how plasma concentration monitoring of individual antiarrhythmic agents is affected by the presence of active metabolites, optical isomers differing in their activity and variations in protein binding, is essential in interpreting data obtained from plasma concentration monitoring.
Collapse
Affiliation(s)
- R L Woosley
- Department of Pharmacology, Georgetown University School of Medicine, Washington D.C. 20007
| |
Collapse
|
9
|
Platia EV, Weisfeldt ML, Franz MR. Immediate quantitation of antiarrhythmic drug effect by monophasic action potential recording in coronary artery disease. Am J Cardiol 1988; 61:1284-7. [PMID: 3376887 DOI: 10.1016/0002-9149(88)91170-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A contact electrode catheter, which permits clinical recording of cardiac monophasic action potentials (MAPs), was used as a means of quantifying the electrophysiologic effect of 2 antiarrhythmic drugs, procainamide and quinidine. MAP recordings were made in continuous fashion from the right ventricle in 16 patients, before and after the intravenous administration of procainamide (11 patients) or quinidine (5). Increases in the MAP duration at 90% repolarization (MAPD90) were used as indexes of drug effect and related to plasma drug level. Surface electrocardiographic (QRS duration, corrected QT interval [QTC]) and electrophysiologic (ventricular effective refractory period) measurements, in addition to MAPD90, were made at the same time as blood sampling for plasma drug level determination. Dose response curves, plotting change in MAPD90 versus plasma drug level, showed strong linear correlation for both procainamide (p less than 0.0001) and quinidine (p less than 0.0001). The variance (error of estimation) of the predictive relation, change in MAPD90 versus plasma drug level, was significantly lower than that of change in QTC (p less than 0.001), QRS duration (p less than 0.0001) or ventricular effective refractory period (p less than 0.0001) versus plasma drug level for both procainamide and quinidine. Changes in MAP duration closely correlate with plasma drug level, and as such, may serve as an immediate, quantitative indicator of myocardial drug effect during the administration of antiarrhythmic agents.
Collapse
Affiliation(s)
- E V Platia
- Cardiology Division, Johns Hopkins Medical Institutions, Baltimore, Maryland
| | | | | |
Collapse
|
10
|
DAVY J, WEISSENBURGER J, ERTZBISCHOFF O, POIRIER J, BIOUR M, GAYET J, CHEYMOU G, MOTTE G. Comparison of Electrophysiological Effects of Quinidine and Hydroquinidine in Anesthetized Dogs. J Cardiovasc Electrophysiol 1988. [DOI: 10.1111/j.1540-8167.1988.tb01455.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Carmeliet E. Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide. Eur J Pharmacol 1987; 133:29-36. [PMID: 3556390 DOI: 10.1016/0014-2999(87)90202-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The effects of lorcainide and its metabolite norlorcainide on the maximal rate of depolarization (Vmax) were compared at different rates of stimulation and at various membrane potentials in ventricular muscle preparations of guinea-pig heart. A standard microelectrode technique was used. The results show that lorcainide and norlorcainide exerted qualitatively similar effects; they both depressed Vmax in a frequency- and potential-dependent way. The following quantitative differences were found: lorcainide was about 50% more potent in depressing Vmax; this difference in potency was observed at 1 and 2 Hz stimulation rates; the block by lorcainide was clearly potential-dependent; in the case of norlorcainide this effect was weak; the onset and removal of block were about twice as fast with lorcainide; the block per action potential was greater with lorcainide. The electrophysiological effects were decreased in the presence of alpha 1-acid glycoprotein, though to a similar extent with both drugs. Taking into account the difference in potency found in the present experiments and the difference in plasma concentration described in the literature, it is concluded that the parent drug and its metabolite both contribute to about the same extent to the in vivo effect of oral treatment with lorcainide.
Collapse
|
12
|
Van Lith RM, Appleby DH. Quinidine-nifedipine interaction. DRUG INTELLIGENCE & CLINICAL PHARMACY 1985; 19:829-31. [PMID: 4064916 DOI: 10.1177/106002808501901107] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Quinidine pharmacokinetics are known to be altered by a number of drugs. We present a case where dose-related increases in quinidine serum concentrations were significantly suppressed by concurrent nifedipine therapy. Clinicians should be alert to the possibility of an alteration in quinidine serum concentrations when instituting or discontinuing nifedipine in patients receiving quinidine.
Collapse
|
13
|
Selinger K, Crawhall JC. Determination of the metabolites of mexiletine in human plasma. J Pharm Biomed Anal 1985; 3:547-53. [PMID: 16867646 DOI: 10.1016/0731-7085(85)80072-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/1984] [Revised: 02/25/1985] [Indexed: 10/18/2022]
Abstract
A liquid chromatographic method for the determination of mexiletine and unconjugated metabolites in plasma has been developed. A reversed-phase C18 column is used with isocratic elution and either UV or amperometric detection. Sample pretreatment involves double extraction of the metabolites. The method enables the measurement of four mexiletine metabolites at levels as low as 10 ng ml(-1), with both precision and accuracy of about 6%. Forty-nine samples from patients receiving mexiletine were analysed. Metabolite VII was found to be the major metabolite (mean concentration 225 ng ml(-1)), metabolites IX and VI were also found at mean concentrations of 95 and 10 ng ml(-1), respectively, whilst metabolite VIII was not detected.
Collapse
Affiliation(s)
- K Selinger
- Division of Clinical Biochemistry, Royal Victoria Hospital and McGill University, 687 Pine Avenue West, Montreal, Quebec, H3A 1A1, Canada
| | | |
Collapse
|
14
|
Abstract
This article discusses ventricular tachycardia with reference to the various proposed mechanisms, diagnosis, and management. Criteria for the diagnosis of ventricular tachycardia caused by reentry, automaticity, and triggered activity are presented. The use of various drugs as well as the role of electrophysiologic testing is discussed.
Collapse
|